Longboard Pharmaceuticals to Participate in Upcoming Investor Conferences
September 01 2022 - 4:01PM
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that members of its senior leadership team will participate in the
Citi Annual BioPharma Conference, which is taking place September
7-8, 2022, in Boston, MA, and participate in a fireside chat at the
H.C. Wainwright Global Investment Conference, which is taking place
September 12-14, 2022, in New York City.
Presentation
Details:Title: Citi 17th Annual BioPharma
ConferenceDetails: Hosting investor meetings
Thursday, September 8, 2022
Title: H.C. Wainwright 24th
Annual Global Investment Conference Details:
Participating in a fireside chat on Wednesday, September 14, at
2:30 PM ET (Kennedy II) and hosting investor meetings Tuesday,
September 13 – Wednesday, September 14, 2022
To access a webcast of the H.C. Wainwright
presentation, please visit the “Events & Presentations” page
within the Investors Relations section of Longboard’s website at
https://www.longboardpharma.com/. The fireside chat will be webcast
live and archived on the website for at least 30 days following the
event.
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of
GPCR research. Longboard is evaluating LP352, an oral, centrally
acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with
negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes,
in development for the potential treatment of seizures associated
with a broad range of developmental and epileptic encephalopathies.
Longboard is also evaluating LP659, a centrally acting,
sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator,
in development for the potential treatment of multiple neurological
diseases, and LP143, a centrally acting, full cannabinoid type 2
receptor (CB2) agonist, in development for the potential treatment
of central nervous system (CNS) diseases and disorders.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about Longboard’s
participation in the upcoming conferences, Longboard’s clinical and
preclinical programs, ability to develop and deliver medicines, and
focus. For such statements, Longboard claims the protection of the
Private Securities Litigation Reform Act of 1995. Actual events or
results may differ materially from Longboard’s expectations.
Factors that could cause actual results to differ materially from
those stated or implied by Longboard’s forward-looking statements
are disclosed in Longboard’s filings with the Securities and
Exchange Commission (SEC). These forward-looking statements
represent Longboard’s judgment as of the time of this release.
Longboard disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Corporate Contact:
Megan E. Knight
Head of Investor Relations
mknight@longboardpharma.com
IR@longboardpharma.com
619.592.9775
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024